M. Peter Marinkovich
Quick facts
Marketed products
- Efgartigimod · Immunology · revenue 2500
Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about M. Peter Marinkovich
What are M. Peter Marinkovich's marketed drugs?
Top marketed products include Efgartigimod.
Related
- Efgartigimod · Immunology
- Sector hub: All tracked pharma companies